4 days Ago By ABMN Staff
Verve Therapeutics ( NASDAQ:VERV – Free Report ) had its price target upped by Canaccord Genuity Group from $32.00 to $39.00 in a research report report published on Tuesday morning, Benzinga reports.
They currently have a buy rating on the stock. VERV has been the subject of a number of other reports. Royal Bank of Canada cut their price target on Verve Therapeutics from $17.
00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, March 4th. Guggenheim reaffirmed a “buy” rating on shares of Verve Therapeutics in a research report on Tuesday, March 25th.
HC Wainwright boosted their target price on shares of Verve Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday.
Finally, William Blair restated an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $25.75.
View Our Latest Analysis on Verve Therapeutics Verve Therapeutics Stock Performance Verve Therapeutics ( NASDAQ:VERV – Get Free Report ) last issued its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.
72) by $0.14. Verve Therapeutics had a negative net margin of 807.
65% and a negative return on equity of 35.23%. The company had revenue of $13.
08 million during the quarter, compared to analyst estimates of $3.94 million. Sell-side analysts predict that Verve Therapeutics will post -2.
49 EPS for the current year. Hedge Funds Weigh In On Verve Therapeutics Institutional investors have recently modified their holdings of the company. KFG Wealth Management LLC acquired a new position in Verve Therapeutics in the 1st quarter valued at $46,000.
Merit Financial Group LLC lifted its position in Verve Therapeutics by 125.6% during the 1st quarter. Merit Financial Group LLC now owns 27,206 shares of the company’s stock worth $124,000 after acquiring an additional 15,146 shares during the last quarter.
Green Alpha Advisors LLC boosted its holdings in Verve Therapeutics by 85.1% during the first quarter. Green Alpha Advisors LLC now owns 54,492 shares of the company’s stock valued at $249,000 after acquiring an additional 25,054 shares during the period.
GAMMA Investing LLC increased its stake in shares of Verve Therapeutics by 454.0% in the first quarter. GAMMA Investing LLC now owns 33,539 shares of the company’s stock worth $153,000 after purchasing an additional 27,485 shares during the period.
Finally, Wellington Management Group LLP lifted its position in shares of Verve Therapeutics by 4.2% during the 4th quarter. Wellington Management Group LLP now owns 361,498 shares of the company’s stock worth $2,039,000 after purchasing an additional 14,469 shares during the last quarter.
Institutional investors own 97.11% of the company’s stock. Verve Therapeutics Company Profile ( Get Free Report ) Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States.
The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. Featured Stories Receive News & Ratings for Verve Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verve Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
